At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 9 enrolled
Drug / intervention
Alfilberceptdrug
Likely dose
Alfilbercept 2.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD
Vitreous -Retina- Macula Consultants of New York·interventional·Posted Dec 19, 2011·Updated Sep 7, 2018
In Brief
A Phase 4 clinical trial evaluating Alfilbercept for AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy). Completed, enrolled 9 participants across 1 site.
Detailed Summary
This is an open label study to evaluate intravitreally administered 2.0 mg intravitreal aflibercept injection in patients who have been previously treated for AMD and have persistent or recurrent fluid despite monthly intravitreal anti-VEGF therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionMar 2013
TodayJul 2026
First PostedDec 19, 2011
Enrollment StartDec 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.5 years ago
Interventions
Alfilberceptdrug
All patients will receive 2.0 mg intravitreal aflibercept injection.